Your browser doesn't support javascript.
loading
Metastatic breast cancer survival improvement restricted by regional disparity: Surveillance, Epidemiology, and End Results and institutional analysis: 1990 to 2011.
Malmgren, Judith A; Calip, Gregory S; Atwood, Mary K; Mayer, Musa; Kaplan, Henry G.
Afiliação
  • Malmgren JA; HealthStat Consulting, Inc., Seattle, Washington.
  • Calip GS; Department of Epidemiology, University of Washington, Seattle, Washington.
  • Atwood MK; Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, Illinois.
  • Mayer M; Swedish Cancer Institute, Seattle, Washington.
  • Kaplan HG; Metastatic Breast Cancer Alliance, New York, New York.
Cancer ; 126(2): 390-399, 2020 01 15.
Article em En | MEDLINE | ID: mdl-31639221
BACKGROUND: The extent of breast cancer outcome disparity can be measured by comparing Surveillance, Epidemiology, and End Results (SEER) breast cancer-specific survival (BCSS) by region and with institutional cohort (IC) rates. METHODS: Patients who were diagnosed with a first primary, de novo, stage IV breast cancer at ages 25 to 84 years from 1990 to 2011 were studied. The change in 5-year BCSS over time from 1990 to 2011 was compared using the SEER 9 registries (SEER 9) without the Seattle-Puget Sound (S-PS) region (n = 12,121), the S-PS region alone (n = 1931), and the S-PS region IC (n = 261). The IC BCSS endpoint was breast cancer death confirmed from chart and/or death certificate and cause-specific survival for SEER registries. BCSS was estimated using the Kaplan-Meier method. Hazard ratios (HzR) were calculated using Cox proportional-hazards models. RESULTS: For SEER 9 without the S-PS region, 5-year BCSS improved 7% (from 19% to 26%) over time, it improved 14% for the S-PS region (21% to 35%), and it improved 27% for the S-PS IC (29% to 56%). In the IC Cox proportional-hazards model, recent diagnosis year, chemotherapy, surgery, and age <70 years were associated with better survival. For SEER 9, additional significant factors were white race and positive hormone receptor status and S-PS region was associated with better survival (HzR, 0.87; 95% CI, 0.84-0.90). In an adjusted model, hazard of BC death decreased in the most recent time period (2005-2011) by 28% in SEER 9 without S-PS, 43% in the S-PS region and 45% in the IC (HzR, 0.72 [95% CI, 0.67-0.76], 0.57 [95% CI, 0.49-0.66], and 0.55 [95% CI, 0.39-0.78], respectively). CONCLUSIONS: Over 2 decades, the survival of patients with metastatic breast cancer improved nationally, but with regional survival disparity and differential improvement. To achieve equitable outcomes, access and treatment approaches will need to be identified and adopted.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias da Mama / Programa de SEER / Disparidades em Assistência à Saúde Tipo de estudo: Prognostic_studies / Screening_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged País/Região como assunto: America do norte Idioma: En Revista: Cancer Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias da Mama / Programa de SEER / Disparidades em Assistência à Saúde Tipo de estudo: Prognostic_studies / Screening_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged País/Região como assunto: America do norte Idioma: En Revista: Cancer Ano de publicação: 2020 Tipo de documento: Article